mAB
Financiado
many(Anti)Bodies
Many of the exceptional breakthroughs in pharmaceutics require the collective and interdisciplinary effort of the scientific community to overcome challenges and shortcomings involved in optimizing the formulation of the final pro...
Many of the exceptional breakthroughs in pharmaceutics require the collective and interdisciplinary effort of the scientific community to overcome challenges and shortcomings involved in optimizing the formulation of the final product. Monoclonal antibodies, for instance, have been found to be highly effective for the treatment of various immunological and allergic diseases as well as for cancer treatments thanks to their high specificity. On the other hand, they typically present high viscosities in concentrated solutions, dramatically altering their flow properties. The direct consequence is the difficulty in preparing stable solutions suitable for subcutaneous self-administration which, compared to intravenous infusion, would be advantageous in terms of patient compliance and adherence to the treatment, and reduced healthcare costs. Currently, a univocal framework providing microscopic interpretation to the enhanced viscosity is missing. With my proposal many(Anti)Bodies, I aim to address this issue by putting forward an interdisciplinary approach which exploits soft matter and colloidal science to investigate the molecular origin of the observed macroscopic behavior in antibody solutions. By combining numerical simulations with experiments, I will first design an accurate single-molecule model that accounts for the anisotropic shape of the antibody and include all relevant ingredients that determine intermolecular interactions. Therefore, through advanced computational techniques, I will be able to bring the current understanding of the antibody collective behavior and rheological properties to a new level, by shedding light on their dynamics and self-association in crowded environments. With the direct collaboration of pharmaceutical industries, my proposal will ultimately guide the formulation of novel antibody-based biologics and inspire future studies where the features of the antibody are designed according to the desired solution properties.
ver más
Duración del proyecto: 32 meses
Fecha Inicio: 2023-03-20
Fecha Fin: 2025-11-30
Fecha Fin: 2025-11-30
Línea de financiación: concedida
El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-03-20
Línea de financiación objetivo
El proyecto se financió a través de la siguiente ayuda:
HORIZON-MSCA-2022-PF-01-01:
MSCA Postdoctoral Fellowships 2022
Cerrada
hace 2 años
Presupuesto
El presupuesto total del proyecto asciende a
207K€
Líder del proyecto
LUNDS UNIVERSITET
No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico
TRL
4-5
Perfil tecnológico
TRL
4-5